Insight into the status of plasma renin and aldosterone measurement: findings from 526 clinical laboratories in China
Author:
Zhou Weiyan1ORCID, Deng Yuhang1ORCID, Ma Wenjun2, Zhao Haijian1, Wang Kaijun2ORCID, Zhang Qian3, Gan Wei4, Chen Wenxiang1, Cai Jun5, Zhang Chuanbao1ORCID
Affiliation:
1. 12501 National Center for Clinical Laboratories , Institute of Geriatric Medicine , Chinese Academy of Medical Sciences , Beijing Hospital/ National Center of Gerontology , Beijing , P.R. China 2. National Center for Cardiovascular Diseases & Fuwai Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College , Beijing , P.R. China 3. Department of Clinical Laboratory , Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences , Beijing , P.R. China 4. Department of Laboratory Medicine , West China Hospital, Sichuan University , Chengdu , P.R. China 5. Beijing Anzhen Hospital, Capital Medical University , Beijing , P.R. China
Abstract
Abstract
Objectives
Accurate measurements of renin and aldosterone levels play an important role in primary aldosteronism screening, which is of great importance in the management and categorization of hypertension. The objective of this study is to investigate the current status of plasma renin and aldosterone measurements in China, which is achieved by analyzing the results of 526 clinical laboratories nationwide for three pooled fresh plasma samples derived from more than 2,000 patients.
Methods
Renin and aldosterone in three pooled plasma samples were measured four times in 526 laboratories employing various measurement systems. The inter- and intra-laboratory %CV were calculated and compared. To determine the source of the substantial inter-laboratory %CV, laboratories were categorized according to the measurement systems they are using, and both the inter- and intra-measurement-system %CV were calculated and compared.
Results
Regarding renin, the majority of laboratories use four primary commercial immunoassays. However, for aldosterone, in addition to commercial immunoassays, laboratory-developed liquid chromatography-tandem mass spectrometry (LC-MS) methods are also used by laboratories. The median values of intra-laboratory %CVs, intra-measurement-system %CVs, inter-laboratory %CVs, and inter-measurement systems %CVs varied between 1.6 and 2.6 %, 4.6 and 14.9 %, 8.3 and 25.7 %, and 10.0 and 34.4 % for renin, respectively. For aldosterone, these values ranged from 1.4 to 2.2 %, 2.5–14.7 %, 9.9–31.0 %, and 10.0–35.5 %, respectively.
Conclusions
The precision within laboratories and measurement systems for plasma renin and aldosterone measurements is satisfactory. However, the comparability between laboratories using different measurement systems remains lacking, indicating the long way to achieve standardization and harmonization for these two analytes.
Publisher
Walter de Gruyter GmbH
Reference21 articles.
1. Yin, R, Yin, L, Li, L, Silva-Nash, J, Tan, J, Pan, Z, et al.. Hypertension in China: burdens, guidelines and policy responses: a state-of-the-art review. J Hum Hypertens 2022;36:126–34. https://doi.org/10.1038/s41371-021-00570-z. 2. Funder, JW, Carey, RM, Mantero, F, Murad, MH, Reincke, M, Shibata, H, et al.. The management of primary aldosteronism: case detection, diagnosis, and treatment: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2016;101:1889–916. https://doi.org/10.1210/jc.2015-4061. 3. Monticone, S, Burrello, J, Tizzani, D, Bertello, C, Viola, A, Buffolo, F, et al.. Prevalence and clinical manifestations of primary aldosteronism encountered in primary care practice. J Am Coll Cardiol 2017;69:1811–20. https://doi.org/10.1016/j.jacc.2017.01.052. 4. Funder, JW. Primary aldosteronism: present and future. Vitam Horm 2019;109:285–302. https://doi.org/10.1016/bs.vh.2018.10.006. 5. Monticone, S, D’Ascenzo, F, Moretti, C, Williams, TA, Veglio, F, Gaita, F, et al.. Cardiovascular events and target organ damage in primary aldosteronism compared with essential hypertension: a systematic review and meta-analysis. Lancet Diabetes Endocrinol 2018;6:41–50. https://doi.org/10.1016/s2213-8587(17)30319-4.
|
|